First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin

Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy

VANCOUVER, Washington, Jan. 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its clinical trials evaluating leronlimab for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC).

New data from the first patient enrolled in the Company's metastatic triple-negative breast (mTNBC) Phase 1b/2 trial continues to show no detectable levels of circulating tumor cells (CTC) or putative metastatic cells in the peripheral blood following 15 weeks of treatment with leronlimab in combination with carboplatin.

The second patient, enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, showed a 50 percent shrinkage of the primary tumor and no new metastasis in the brain after treatment with leronlimab as a monotherapy. The patient was previously treated with pertuzumab and trastuzumab for over a year and a half. This patient has been taking leronlimab since November 25, 2019 with one 700 mg dose each week.

"Recent testing of the first patient demonstrated continued absence of CTCs in all blood tubes with only one cancer-associated macrophage like cells (CAMLs) in one of two tubes. In the second patient, the follow up brain scan conducted on January 17, 2020, showed that the largest brain lesion had a greater than 4-fold reduction in size," said Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn. "Other smaller lesions on the second patient's brain have not changed in size and cerebral edema remains at decreased levels since the last imaging studies. Taken together, these results suggest continued response of both primary and metastatic tumors to treatment with leronlimab for both the first and second patient."

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added: "We are thrilled to see these additional data that further support leronlimab as a potential treatment option for patients with mTNBC and MBC. As a Company, we look forward to continuing our work in the oncology space and developing a potentially safe and effective treatment option for patients suffering from this deadly disease."

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene.1TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur.2,3Since the triple negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.4Currently, there are no targeted therapies approved to treat triple negative breast cancer.5

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab (PRO 140) as a once-weekly monotherapy for HIV-infected patients and, plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab (PRO 140) can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Company's cash position, (ii)the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv)the Company's ability to enter into partnership or licensing arrangements with third parties, (v)the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Company's ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Company's clinical trials, (viii)the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Company's control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSMedia:Grace FotiadesLifeSci Communicationsgfotiades@lifescicomms.com (646) 876-5026

Investors: Nader Pourhassan, Ph.D.President & CEOnpourhassan@cytodyn.com

Read the original post:
Impressive Results Continue from CytoDyn's Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC - Benzinga

Bone Marrow Stem Cells Comments Off on Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC – Benzinga | January 22nd, 2020

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Planning To Lay Down Future Strategy? Request Brochure Of Cell Separation Technology Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

To Obtain All-Inclusive Information On Forecast Analysis Of Cell Separation Technology Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1925

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Visit link:
Cell Separation Technology Market to Receive Overwhelming Hike in Revenues by 2027 Dagoretti News - Dagoretti News

Cardiac Stem Cells Comments Off on Cell Separation Technology Market to Receive Overwhelming Hike in Revenues by 2027 Dagoretti News – Dagoretti News | January 20th, 2020

Global Exosome Therapeutic Marketreport identifies and analyses the emerging trends along with major drivers, challenges and opportunities in industry with analysis on Market trends, share, growth,demand, top vendors, Geographical Regions, types, applications. Exosome Therapeutic industry report gives a comprehensive account of the Global Exosome Therapeutic market. Details such as the size, key players, segmentation, SWOT analysis, most influential trends, and business environment of the market are mentioned in this report.

Exosome Therapeutic Marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Download Exclusive PDF Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=glo

Synopsis of Global Exosome Therapeutic Market:-Exosomes is used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Some Of The Major Competitors Currently Working In Global Exosome Therapeutic Market Are:Bayer AG, Iso-Tex Diagnostics, Inc., Bracco Diagnostic Inc., Novalek Pharmaceuticals Pvt. Ltd., iMAX, Taejoon Pharm, Unijules Medicals Ltd, General Electric, Guerbet LLC, J.B.Chemicals & Pharmaceuticals Ltd among others players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

For More Information or Query or Customization Before Buying, Visit @https://www.databridgemarketresearch.com/inquire-before-buying/?dbm

North America Dominates The Exosome Therapeutic Market as the U.S. Is leaderin exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Browse in-depth TOC on Exosome Therapeutic Market

50 Tables

250 No of Figures

150 Pages

This Exosome Therapeutic Market report contains all aspects that are directly or indirectly related to the multiple areas of the global market. Our experts have carefully collated the global Exosome Therapeutic Market data and estimated the change in the forecast period. This information in the report helps customers make accurate decisions about market activity Exosome Therapeutic Market based on forecasting trends. This report also discusses current or future policy research or regulations that must be initiated by management and market strategies.

Buy This Report (Single User Access)@https://www.databridgemarketresearch.com/checkout/buy/singleuser/gl

Global Exosome Therapeutic Market Scope and Market Size

Global Exosome Therapeutic Market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.To be continued..Detailed Segmentation ofExosome Therapeutic Market

The Countries Covered In The Exosome Therapeutic Market Report Are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, South Africa, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil and Rest of South America as part of South America.

Along with the elaborated information about the key contenders, the globalExosome Therapeutic Marketreport efficiently provides information by segmenting the market on the basis of the type services and products offerings, form of the product, applications of the final products, technology on which the product is based, and others. The report is also bifurcated the market on the basis of regions to analyze the growth pattern of the market in different geographical areas.

The Exosome Therapeutic Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Exosome Therapeutic Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

Global Exosome Therapeutic Market Report includes Detailed TOC points:

1 Introduction

2Market Segmentation

3 Market Overview

3.3 Opportunities

4 Executive Summaries

5 Premium Insights

6 Regulatory Procedure

7 Global Exosome Therapeutic Market, By Type

8 Global Exosome Therapeutic Market, by disease type

9 Global Exosome Therapeutic Market, By Deployment

10 Global Exosome Therapeutic Market, By End User

11 Global Exosome Therapeutic Market, By Distribution Channel

12 Global Exosome Therapeutic Market, By Geography

13 Global Exosome Therapeutic Market, Company Landscape

14 Company Profile

Continued!!!

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See the rest here:
Exosome Therapeutic Market 2020 Modest Situation among the Top Manufacturers, With Sales, Revenue and Market Share 2026 Dagoretti News - Dagoretti...

Cardiac Stem Cells Comments Off on Exosome Therapeutic Market 2020 Modest Situation among the Top Manufacturers, With Sales, Revenue and Market Share 2026 Dagoretti News – Dagoretti… | January 20th, 2020

Warsaw (AFP)

Poland has emerged as Europe's leader in stem cell storage, a billion-dollar global industry that is a key part of a therapy that can treat leukaemias but raises excessive hopes.

Submerged in liquid nitrogen vapour at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukaemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industry's leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

- Health insurance -

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukaemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sister's stem cells into Michal's bloodstream.

It was not quite enough for Michal's needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, "is now flourishing, both intellectually and physically," his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, "each container holds up to 10,000 blood bags... Safe and secure, they wait to be used in the future," its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the "blood will be ready to use without the whole process of looking for a compatible donor and running blood tests," the biologist told AFP.

For families who have paid an initial nearly 600 euros ($675) and then an annual 120 euros to have the blood taken from their newborns' umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

- Beauty products -

Haematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as "sellers of hope", who "make promises that are either impossible to realise in the near future or downright impossible to realise at all for biological reasons."

He compares them to makers of beauty products who "swear their cream will rejuvenate the client by 20 years."

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

"There is a list of almost 80 diseases for which stem cells could prove beneficial," US haematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood programme Vitalant in New Jersey, told AFP.

"But given the present state of medicine, they are effective only for around a dozen of them, like leukaemia or cerebral palsy," he said.

"It's not true, as it's written sometimes, that we can already use them to fight Parkinson's disease or Alzheimer's disease or diabetes."

EuroStemCell also cautions against private blood banks that "advertise services to parents suggesting they should pay to freeze their child's cord blood... in case it's needed later in life."

"Studies show it is highly unlikely that the cord blood will ever be used for their child," the network said.

It also pointed out that there could be a risk of the child's cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most EU countries however permit it while imposing strict controls.

- Rapid growth -

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with two million zlotys (around 450,000 euros, $525,000), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35 percent of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKM's chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.

2020 AFP

Read more:
Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24

Bone Marrow Stem Cells Comments Off on Europe’s guardian of stem cells and hopes, real and unrealistic – FRANCE 24 | January 20th, 2020

The first six months of his young life have been a roller-coaster but Mighty Hudson Cowie is back home in Alberta after an experimental gene therapy procedure in Tennessee was successful.

Its been so long since weve got to see our family, our friends, Hudsons dad Ian said. Even just to be able to show him off to everybody. Weve spent the last six months seeing how amazing of a little guy he is.

Now we finally get to share that with everybody.

Hudson was diagnosed with Severe Combined Immunodeficiency (SCID) within days of his birth on June 23. The condition, known to many as Bubble Boy Disease, prevents his body from fighting illnesses. Essentially, he didnt have an immune system.

READ MORE:Hundreds attend donor drive for Mighty Hudson, Alberta baby with rare immune disease

In August, Hudson was accepted into a gene therapy program at St. Jude Childrens Research Hospital in Memphis. A medical team removed some of his bone marrow cells and replaced the faulty gene with a corrected one. The cells were placed back into his body through an IV.

Story continues below advertisement

They took his own bone marrow out in his bone marrow, hes got hematopoietic stem cells. They were able to take those cells and modify them to create a product, a repaired version of those cells, and then give them back to him, Ian told Global News on Monday.

Medicine is amazing. We took a chance on science and were so glad that we did. Its amazing what theyre able to do.

Ian and his wife Hayley were weighing two options for their little boy: using donor cells or a revamped version of Hudsons own cells. They decided on the second, which meant a trial at St. Judes.

We weighed the pros and cons of both options and for us, [and] personally, we decided that gene therapy seemed like the safer way to go, Ian said.

It didnt rely on a donor, it was the new up-and-coming medicine, the existing results for gene therapy were already incredibly promising and then, as an added bonus, it had substantially less chemotherapy requirements.

Story continues below advertisement

WATCH: (Sept. 9, 2019) A Morinville baby with a rare disorder received a life-changing procedure in the U.S. Hudson Cowies parents give Su-Ling Goh an update on therapy for his immune system.

It honestly sounded too good to be true, Hayley added.

With bone marrow transplant, we heard of graft versus host disease, where its somebody elses cells and they can reject them. With gene therapy, having his own cells, he wasnt going to reject them because his body already knows them.

A few months after the transplant, they started to see results: Hudsons first T-cells, a type of white blood cell thats a key component of the immune system.

From three months, it exploded. At four months, it was even more T-cells. The growth was exponential, Ian said.

Story continues below advertisement

I think thats the thing every doctor hopes to get to say to their patients one day: Hes cured. And the day that we left Memphis, she said that. She said: Hes cured.

We squealed like little schoolgirls. It was very exciting.

Hudsons immune system right now can be compared to that of a newborn baby.

As hes introduced to small bugs, itll just keep growing and growing and be normal, Hayley explained.

There are still unknowns, but the family is very hopeful.

He was Patient 12 on the trial and from what we were informed, everyone on the trial has done tremendously well, Ian said.

I just think its amazing, Hayley added. Its amazing that we were the first ones who got on newborn screening and that this trial was even available for us. It just seems that everything completely lined up.

Story continues below advertisement

I feel like everything has just fallen into place to get him cured.

The treatment is just amazing. Our doctors are brilliant, its just all incredible and hes doing great.

Hudson was one of the first babies to be screened for SCID through a new program. Since SCID was added in May 2019, the Alberta Health Services Newborn Metabolic Screening Program has screened over 34,000 newborns and has diagnosed four cases of SCID.

While very much welcome, being home is still a big change for the Cowies.

Im still processing, even now, Hayley said. Its nice to go see people but we were in isolation for so long that it doesnt just flip all of a sudden. I know were still really protective and we can hear a cough from miles away.

Story continues below advertisement

It was surreal to leave but I feel like Im still dreaming a little bit.

They havent attempted any big outings yet especially given its flu season but they have been able to go to some family dinners.

Its an adjustment for sure, but a good adjustment, Hayley said. He loves people Hes always just smiling and playful hes just happy.

The Cowies will be back in Tennessee for one day for a checkup this weekend. Hudson will have another checkup with the St. Judes team next month. Hell have followups at least once a year until hes 10 years old.

2020 Global News, a division of Corus Entertainment Inc.

See the original post:
Alberta baby Mighty Hudson home after gene therapy: hes cured - Global News

Bone Marrow Stem Cells Comments Off on Alberta baby Mighty Hudson home after gene therapy: hes cured – Global News | January 20th, 2020

Research team leader Marina Gomzikova, employee of the Gene and Cell Technologies Lab, started working on extracellular microvesicles (ECMVs) in 2013, when she was enrolled in her PhD course. Since then, very promising properties were found in ECMVs derived from human mesenchymal stem cells (MSCs).

ECMVs are microstructures surrounded by a cytoplasm membrane; they have proven to be a prospective therapeutic tool due to their biocompatibility, miniature size, safety, and regenerative properties. Microvesicles can be applied to circumvent the existing limitations in cell therapy without losing in effectiveness. At Kazan Federal University, cytochalasin B-induced membrane vesicles (CIMVs) are currently studied. They are derived from mesenchymal stem cells, which are very similar to natural ECMVs.

In this paper, the authors produced, studied and characterized the biological activity of MSC-derived CIMVs. A number of biologically active molecules were found in CIMVs, such as growth factors, cytokines, and chemokines; their immunophenotype was also described. Most importantly, CIMVs were found to stimulate angiogenesis, the growth of blood vessels, in the same way as stem cells.

Therefore, the team believes that human CIMVs-MSCs can be used for cell free therapy of degenerative diseases. CIMVs-MSCs are able to induce therapeutic angiogenesis, which is necessary for the treatment of ischemic tissue damage (for example, ischemic heart disease, hind limb ischemia, diabetic angiopathies, and trophic ulcers) and stimulate regeneration processes in cases of skin damage (wounds and burns), neurodegeneration (multiple sclerosis and Alzheimer's disease), or traumatic injuries (damage of peripheral nerves and spinal cord injury).

Gomzikova's group continues to research the therapeutic potential artificial microvesicles for autoimmune diseases. Vector properties, i. e. the capacity for delivery, of vesicles for tumor therapy is also of interest.

CIMVs can become a new therapeutic tool in regenerative medicine and a new class of effective and safe medications.

Continue reading here:
Studies of membrane vesicles pave the way to innovative treatments of degenerative diseases - Science Codex

Spinal Cord Stem Cells Comments Off on Studies of membrane vesicles pave the way to innovative treatments of degenerative diseases – Science Codex | January 20th, 2020

The birds and the bees as we know them are changing. A new process called in vitro gametogenesis (IVG) is currently being developed, and if successful, it will completely transform the way humans think about reproduction.

In 20 to 40 years, people will still have sex. But when they want to make babies, theyll go to a lab, predicts Stanford University Professor Henry T. Greely. Its also the premise of his book The End of Sex and the Future of Human Reproduction.

The process of IVG creates sperm and egg cells in a lab from just about any adult cell. IVG uses skin or blood cells to reverse engineer a special type of cells calledinduced pluripotent stem cells(iPSCs).

IVG could eliminate the need for egg and sperm donors. With IVG, post-menopausal women could generate viable eggs. Same-sex couples could make a biological family. Virtually anyone with skin would have the ability to produce eggs or sperm.

Although 40 years might seem a lifetime away, theres a lot to figure out before we can safely, ethically, and responsibly add in vitro gametogenesis to our list of fertility treatment options.

Read full, original post: IVG: Making Babies From Skin Cells

Originally posted here:
Video: In 40 years, babies could be made in the lab from skin cells - Genetic Literacy Project

Skin Stem Cells Comments Off on Video: In 40 years, babies could be made in the lab from skin cells – Genetic Literacy Project | January 20th, 2020

In 2019, the market size of Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Therapy .

This report studies the global market size of Stem Cell Therapy , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

This study presents the Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Therapy history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Therapy market, the following companies are covered:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Therapy , with price, sales, revenue and global market share of Stem Cell Therapy in 2017 and 2019.

Chapter 3, the Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

More:
Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti...

Skin Stem Cells Comments Off on Product Innovations and Technological Advancements to Boost the Growth of the Stem Cell Therapy Market in the Upcoming Years 2017 2025 Dagoretti… | January 20th, 2020

The Indian Psychiatric Society (IPS) the professional body that represents psychiatrists in India, strongly condemned the use of stem cell therapy in psychiatric disorders, particularly autism, until such a time that research evidence substantiated its effectiveness.

IPS, in its position statement on stem cell therapy on January 17, said that till now, there is no scientifically validated and scrutinized research evidence that proves that stem cells are helpful in any psychiatric disorders including autism.

Autism is a complex neurodevelopmental disorder with no known single cause.

The advisory from the IPS comes at a time when stem cell therapy clinics that claim to have developed stem cell therapies to treat complex psychiatric problems such as autism, cerebral palsy (movement disorder), muscular dystrophy (weakness of muscles), mental retardation, spinal cord injury and brain stroke have mushroomed across the country.

These stem cell therapy centres extract stem cells from the bone marrow of each child and then inject it into the childs spinal canal. The whole procedure takes place under general anaesthesia.

These clinics use aggressive marketing techniques and false claims to lure parents of children who are suffering from disease like autism.

The Indian Council of Medical Research (ICMR) has already published guidelines that cover the various diseases that are applicable for stem cell treatment. No psychiatric disorders, including autism, are listed there under this advisory.

Stem cells are special human cells that have the ability to develop into many different cell types, from muscle cells to brain cells. In some cases, they also have the potential to repair damaged tissues, and provide a cure for various diseases. But the clinical evidence at this point is low.

Psychiatric disorders including autism are combined derangements of both neurodevelopmental and neurodegenerative trajectories of brain and are polygenetic in origin. So they actually are symptomatic manifestations of a variety of different pathogenetic processes about which scientific evidence is as yet inconclusive, IPS said.

Read the original post:
Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com

IPS Cell Therapy Comments Off on Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders – Moneycontrol.com | January 20th, 2020

The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

LEMAITRE VASCULAR INC (LMAT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 80% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BIOLIFE SOLUTIONS INC (BLFS) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firms underlying fundamentals and the stocks valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Motley Fool has returned 639.27% vs. 234.94% for the S&P 500. For more details on this strategy, click here

About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Go here to see the original:
Validea's Top Five Healthcare Stocks Based On Motley Fool - 1/19/2020 - Nasdaq

Cardiac Stem Cells Comments Off on Validea’s Top Five Healthcare Stocks Based On Motley Fool – 1/19/2020 – Nasdaq | January 20th, 2020

Remember being a teenager in high school and thinking 40 was old? I distinctly recall being 15 or 16 years old and thinking Id have it all figured out by the time I was 25. In my mind, Id be a proper grown-up by then in the career of my dreams and married with a baby25 seemed so far away. For the record, I knew nothing at age 25 and felt anything but grown-up. But oh, how quickly time passes. Here I am, a year from turning 40, Ive been married for 12 years, and our son just turned 11. Even now, I cant say with confidence that I feel like an adult. My husband and I still turn to each other with a quizzical expression wondering how we both got here. Im sure many of you reading this can relate.

Of course, the old adage still rings true, and you are only as old as you feel, but even if I dont feel like it, the mirror tells me a different story. Its a daily reminder that time will have her way and you cant stop her. And dont get me wrongIm all about aging gracefully, but I want to look good while I do. For me, its all about taking care of my skin health. Ive been on a cleanse-tone-moisturize-sunscreen routine since I was 14 years old (thanks, Mom!), and its slowly developed into monthly facials, lasers, and a few injectables.

With my big 4-0 coming up, I wanted to try a few buzzy skincare treatments to help turn back the clock a little and make sure my skin looks 100 when the day finally arrives. Read on to find out what Idid along with my honest thoughts, and feel free to DM me at @skinlexicon if you have any questions!

I have already written about my experience with under-eye fillers and lip filler, and I loved both, but Im definitely very careful about who I see for injectables and what filler I use. Most people have some apprehension about trying fillers because there are a lot of examples where it has gone wrong.

Unfortunately, there are a lot of people walking around with filler that you can see and recognize that it was done badly with an unnatural result, says Nancy Samolitis, MD, FAAD, of Facile Dermatology + Boutique in Los Angeles. Because of this, many people have the misconception that all filler treatments will look this way. When the appropriate filler product is used with the correct technique, injected at the correct depth in the correct amount, it should not be visible or look unnatural. This was the case with my experience having a liquid facial. Samolitis chose different types of filler and Botox to suit specific areas of my face to ensure a natural look that still had movement and didnt look stiff or overdone.

There is still a lot of confusion around when/where/how fillers or Botox are used, so I asked Samolitis to settle the debate once and for all.

Botulinum toxin (Botox, Dysport, Xeomin, and Jeuveau are all different brands): "This is what's known as a neuromodulator," Samolitis explains. "That means it binds to a specific receptor in a nerve ending that prevents the nerve from communicating with a muscle, therefore reducing the muscle activity. These products are used to reduce wrinkles that are associated with certain facial movements/expressions. This is most commonly used for areas such as the frown line between the eyebrows (aka the "elevens"), forehead lines, and crow's-feet lines. It can also be used for upper lip lines, chin dimpling, and lines in the neck.

Newer techniques are using these products to create lift by relaxing muscles that are natural depressors in the face and neck. For example, that muscles that pull down on the brows or the jowls can be relaxed to create a very slight lifted look. Even more exciting and new uses for these products include injecting micro-droplets into the skin (instead of the muscle) to reduce oil production in pores, reduce sweating, shrink blood vessels to reduce redness/flushing, and smooth skin texture. There may even be some benefit for treating acne and rosacea, but this is still being studied.

Fillers: These products replace volume. The most commonly used fillers are made of hyaluronic acid, which is a sugar molecule that is bound into a gel-like injectable and placed into various levels of the skin and deeper tissues to replace tissue that we have lost with aging or enhance tissue that we don't have naturally. Certain thicker fillers are used more appropriately on bone and in the fat compartment in the face to create contour (for example, volumizing and contouring the cheeks, temples, and jawline).

"Fillers that are smooth and [bouncier and more elastic] are used for smoothing and plumping lips and around the mouth where there is a lot of movement," Samolitis explains. "If a thicker filler is used in these areas or injected superficially, it can create an unnatural stiff or overly plumped look. Finally, very thin, almost watery, fillers are used to create a hydrated effect in the top layers in the skin or fill in very fine lines or acne scars."

Samolitis used various types of filler and botox around my face during the treatment, and in most cases, she says we need a combination of the products described above to create a harmonious overall result. Signs of aging in the face are usually a combination of volume loss including bone resorption and decreasing the size of the fat pockets that give our face its characteristic shape and thinning of the skin leading to fine lines and texture change, she explains. Injectables should also always be combined with skin rejuvenation techniques including a good skincare regimen, sun protection, and in-office procedures like micro-needle or laser resurfacing. She tells me any medspa that only provides injectables is doing the patient a disservice by not treating the skin and educating the patient on sun and environmental damage. Hear, hear.

The other bonus of getting filler is that it actually helps to create more collagen. The injection creates a tiny wound and a stretching of the cells called fibroblasts in the dermal layer of the skin. This stimulus initiates a cascade of wound-healing signals that ultimately lead to new collagen production. Obviously, this is on a very small scale, but often repeated filler injection in the same area (most commonly the lips, a fine wrinkle, or acne scars) will lead to longer-lasting results over time.

Of course, injectables arent cheap but the good news is, you dont need to get them that often. Botulinum toxin averages three to four months while filler can be anywhere from three months to several years (it depends on the type of filler, area treated, amount of filler used, and the person's metabolism).

If you havent heard ofThe Beauty Sandwich yet then Id suggest checking it out on Instagramstat. The creator,Ivn Pol, is ringing in a new age of noninvasive and nontoxic beauty treatments with his unique skin-tightening methodand the Hollywood A-list are lining up. As a long-time fashion and celebrity makeup artist, Pol wanted an alternative way to reduce the look of wrinkles without needles and saw an opportunity in the market for a natural alternative to "looking our best" and staying young. So he developed The Beauty Sandwich, a unique and customized combination of advanced radiofrequency including monopolar, bipolar, and infrared RF. The method organically plumps and builds collagen to give a filler-like appearance, and Im obsessed!

So whats the magic sauce? Why does it work? While there are a lot of devices out there that show improvement in resurfacing and remodeling the skin, Pol has found that the secret to delivering lasting results is through combining or stacking one procedure on another, just like a sandwich. Pol stacks two radio frequency (RF) devices on top of each other. The first is a monopolar system called Pellev, which means the RF (radio frequency) can penetrate deeply until the tissue reaches a certain temperature. This deep energy (which feels like heat to the client) tightens the skin while at the same time stimulates the fibroblasts, which are the workforce cells that produce new collagen and elastic fibers in the skin.

The second is the eMatrix system, which is a bipolar RF device that limits its energy to the upper levels of the skin. This too stimulates the fibroblasts as well as causes some superficial exfoliation. The combination of the two creates The Sandwich, which gives an immediate tightening effect with the long-term stimulation of the fibroblasts. Add some great topical skincare, and youll get that radiant glow were all after.

But, of course, the big question is, how much does it cost and how long does it last? While the results are case by case, Pol tells me he typically recommends six to eight treatments with touch-ups before big events, but the results can last up to a year or more. They range in price from $850 to $1400, so its not exactly cheap, but when you think about how long it lasts, its comparable to filler, and its completely natural and safe. This is the natural alternative to have a filler-like appearance to the skin, says Pol. I think of The Beauty Sandwich as weight training. We are strengthening and toning the muscles to help with collagen stimulation which plumps and lifts the skin, contouring the face and defining jawline.

As you can see from the pictures, the method shows visible results after just one session, and that continues two weeks after. In fact, I had the post-treatment glow for up to three days after the procedure, but it is the gift that keeps on giving. Pol says four to 15 days after the treatment, your bodys natural reaction to heal comes into play as fibroblasts become present, and the collagen rebuilding process begins. And it continued to do so days, weeks, even months after treatment.

But aside from the aesthetic results, the biggest transformation Pol has seen is in the way women feel about themselves after a series of treatments. That boost in their self-esteem, the voicemails I receive when they love what they see, that empowerment is why I created The Beauty Sandwich, he tells me. I have always believed that beauty comes from within. It starts from the bed and the sheets you sleep on to what you ingest. Same goes for what you put on your skin.

I have been seeing celebrity estheticianMatthew Miller for monthly facials for at least the past year. He is one of my favorites in the L.A. area and definitely the most reasonably priced that Ive found here, too. So when he told me about his new treatment,DermalStem Regeneration, my ears pricked and I immediately booked an appointment with him. In a nutshell, this treatment is an amazing alternative to micro-needling without any pain or downtime. While I was there for the anti-aging effects, it can also help other concerns like acne, hyperpigmentation, and dry skin.

So what is it? Well, DermalStem Regeneration is another treatment that stimulates the growth of, you guessed it, collagen. Firstly, a Bio-Brasion wet/dry microdermabrasion is used to exfoliate the skin. Then he uses a dermastamp to create microchannels on the skins surface. These microchannels allow a serum derived from bone marrow stem cells to penetrate deeper into the skin. Yes, I said bone marrow stem cells! This game-changing serum is packed with next-level growth factors that trigger the skins natural renewal process and promote the formation of collagen and elastin to provide firmness and elasticity. Read: Sign me up! This is quickly followed with a hyaluronic acid serum and 20 minutes of LED to accelerate healing and reduce redness. Both of these together give you the benefits of physical and chemical exfoliation without the irritation or downtime.

Youll see results instantly with this facial, and it just keeps getting better even up to a month post-treatment as the bone marrow stem cells continue to work. You do need to give your body time to produce the collagen to heal the skin after this one, so theres no need to rush back in straight away or sign up for multiple treatments, but Miller says you will see a noticeable difference after three of these. So how much does it cost? The treatment is pricey at $475, but I really do see the value in this one. You can get discounted rates when you buy in bulka three-pack series is $1210, while a six-pack series is $2280.

As I mentioned earlier, I am very picky about who I allow to inject my face. I have seenJennifer Herrmann, MD, twice now for both under-eye fillers and lip fillers, and her work is very subtle and natural. So when I wanted to try the PiQo4 laser to remove a few dark spots, she was my first port of callshe also turned my own blood into an anti-aging serum.

So what is the PiQo4 laser? According to Herrmann, its a picosecond laser thats used to treat unwanted pigmentation and tattoos. It uses energy to target pigment particles, shatters them, and then your bodys immune system helps clear them away, she says. Because it hits its targets so quicklyat picosecond burstsit converts laser light energy into sound almost instantly as it interacts with targets, generating very little heat in the process. This results in less unwanted damage to surrounding tissues, fewer side effects, increased safety for darker skin, and less pain and downtime for patients. In a nutshell, this game-changing laser can pinpoint dark spots and treat them individually without having to treat the entire face. And it works!

But its not just for people with hyperpigmentation like me. You can also use it to remove unwanted tattoos, sunspots, brown spots. In fact, its one of Herrmanns favorite lasers for diffusing brown spots caused by the sun. She also used a fractionated setting on my skin to treat summer sun damage, and it only took one treatmentmy skin is so much clearer and more even. And it only took a week for the dark spots to completely disappear, too.

How many treatments you need all depends on what is being treated. Discrete brown spots can clear in a single treatment, while tattoos can take more than 10 treatments. Prices begin at $250 per session, which is a small price to pay for clearer, healthier skin.

For my fourth treatment, I went to see the much-adored Camille FieldsTyLynn Nguyen is a regular. When you meet Fields, its easy to see why influencers, models, and celebrities book months in advance to have their faces in her magical hands. Fields has been in the industry for 20 years, and her own glowing skin is proof that her treatments and skincare philosophy works. Shes all about strengthening your skin from the inside outSakara and The Beauty Chef products sit proudly alongside her skincare recommendations

Speaking of which, Fields is an officialBiologique Recherche salonthe beloved French skincare line that has a global cult following. Aside fromits groundbreaking, science-based line, Biologique Recherche offers a series of specialty treatments to enhance the effectiveness ofits products, and the Le Grand Soin is the crown jewel. During this treatment, Fields uses specialty boosters, co-factors, masks, serums, and the world-renowned Remodeling Face Machine (the ultimate for firming and lifting the facial muscles), as well as lymphatic and sculptural massage, LED light therapy, and ultrasound. By the end, your face is taut, clear, bright, and glowy. (I have the pictures and videos to prove it!)

All of this will set you back $550, but if you are looking for a treatment that provides long-lasting, skin healthboosting results, this is itmy skin was transformed. But, of course, total skin health is about so much more than just one treatment. As Fields explains, Our skin is just a reflection of our internal health. To truly address the root cause of any skin concern, we have to first look within. Incredible changes can occur when we respect and understand the physiology of our bodies.

Below, I'm sharing the skincare products I used daily to maintain my glow. Keep scrolling to shop my favorite, ride-or-die formulas.

Cosmedix Salicylic Acid Foaming Cleanser ($39)

I love an exfoliating cleanser to slough off dead skin cells to keep blackheads away and keep my skin feeling smooth and fresh. Both of these are also incredibly gentle on the skin and never irritate or dry my skin out. I'm obsessed with Cosmedix's new foaming cleanser. It's a salicylic acid foaming cleanser, but it's so gentle and doesn't have any parabens, which I love.

Cosmedix Purity Balance Exfoliating Prep Toner ($38)

I'm a big fan of using acids, and this one has both of my favorites,salicylic and lactic acids. I have been using this toner for at least 10 years now, and it is truly one of my hero products. I love how it removes excess oil or residue (including makeup) to reveal smooth, clear skin. It can also be used as a spot treatment for breakouts, and I've even used it in lieu of a cleanser when I forgot to pack it on a work trip once. It's really an amazing product.

IS Clinical White Lightening Complex ($145)

I was gifted with this product about two months ago and have been using it every day since.I do think that my skin overall is brighter and firmer. It's really lightweight (a waterlike essence consistency) too, which I like because I use a lot of serums, and if they're too heavy, it can pill, which I loathe. It is also paraben-free.

The other brightening cream I LOVE isSkinMedica'sLytera 2.0 Pigment Correcting Serum ($154). This product really works to help even skin tone and manage pigmentation.I'm super obsessed with even skin tone, so I have several brightening serums in my regimen, includingCosmedix X-Cell($71), which also has niacinamide and microencapsulated Retinol. I love mixing it withitsvitamin C crystals for an added boost.

IS Clinical Super Serum Advance ($155)

This one is also lightweight, but I love it because it has a really high concentration ofL-ascorbic acid (vitamin C), a whopping 15% to be exact. I also love theCosmedixVitamin C Crystals ($32), which you can combine with any serum or moisturizerVersed also has onefor $20.

Cosmedix Refine RX ($78)

I have been using retinol for years, so I can handle the highest-strength version from Cosmedix, but if you're just starting out or have sensitive skin,the brand hasa range of retinol, so you can work your way up.Serum 16($80) is a good place to start.

SkinMedica HA5 Rejuvenating Hydrator ($178)

There are a lot of hyaluronic acid serums out there. I mean a lot. But after trying almost everything out there (well, not all, but a lot!), I consistently come back to this one. It works, plain and simple. I recently started testing out the IS Clinical Hydracool serum after my friend and celebrity estheticianCandace Marinorecommended it. It's packed with hyaluronic acid and feels incredibly cooling to the skinI'm already a convert.

Cosmedix Cell ID ($110)

My estheticianMatthew Millerrecommends this serum to almost everyone. It has really high levels of niacinamide, a form of vitamin B3 that helps tomanage acne, rosacea, pigmentation issues, and wrinkles. This is a really nice everyday defense serum.

IS Clinical Active Serum ($138)

I mix a few drops of this with the IS ClinicalSuper Serum Advance($155) and the White Lightening Serum ($145) morning and night straight after I've toned my skin. I've been doing this for a few months now, and I can honestly say it instantly tightens and brightens my skin. I have definitely noticed a difference. I really love how fresh it makes my skin feel toothe results are immediate. Not sure how I ever lived without it.

Cosmedix X-Age ($160)

I have been using this moisturizer for about a year now, and I notice the difference in my skin texture and overall appearance when I stop using it. This is worth the $$. It has encapsulated vitamin A and a ton of antioxidants to help improve the texture and elasticity of aging skin. I just really love it. I mix it with my face oil every night for added hydration and dewy skin.Humidify($90) is also lovely when I want something hydrating but lightweight.

DMK Seba-E Oil ($0)

I was first introduced to this face oil through Matthew Miller, and I have been hooked on (actually, I think it's safe to say obsessed with)this face oil ever since. I love to mix it with my moisturizer and even reapply it throughout the day for dewy, glowy skin. It can be mixed with makeup too.Mara BeautyAlgae + Moringa Universal Face Oil ($72) is also really beautiful and great mixed with makeup as is the new face 100% organic oil byKohza Numbers(touted as a daily supplement serum withvitamins A, C, and E). It's super lightweight and looks insane when mixed with foundation. I just love it; I just DEW!

Cosmedix Eye Doctor ($130)

This magical eye cream is hands down one of the best out there. I promise. It is like eye cream and a highlighter in one.TheOpti-Eye Crystal ($95) (which is slightly cheaper) is also great and one ofthe brand'sbest-selling products. But I personally prefer the Eye Doctor because it has retinol and feels more targeted to my anti-aging needs.

IS Clinical Eclipse SPF 50 Plus ($45)

This is almost like a mousse in texture. It's light, not too oily, and mixes into the skin without leaving a white residue but also keeps my skin dewy. I love the size of the bottle, and I use it for my face and body. It's paraben-free and doesn't have any active chemical ingredients. Side note: My husband had a terrible reaction tooxybenzone and avobenzone, so if you're sensitive, please look out for that ingredient and avoid sunscreens that have it.

IS Clinical Copper Firming Mist ($35)

I have triedso many face mists, but this is by far my favorite. It does feel firming and is a great spritz to set makeup. I also really loveCosmedixMystic ($42). It smells so good and is incredibly hydrating.

Up next,18 Reasons Kate Bosworth Is Benjamin Buttoning Right Before Our Eyes

This article originally appeared on Who What Wear

Read More from Who What Wear

View original post here:
I Tried 5 Buzzy Skincare Treatments Before My 40th BirthdayHere Are My Reviews - Yahoo Lifestyle

Bone Marrow Stem Cells Comments Off on I Tried 5 Buzzy Skincare Treatments Before My 40th BirthdayHere Are My Reviews – Yahoo Lifestyle | January 19th, 2020

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See more here:
Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News

Bone Marrow Stem Cells Comments Off on Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News – Dagoretti News | January 19th, 2020

Libby Clegg, 29, has represented both Scotland and Great Britain at international sporting events. She won a silver medal at the 2008 Summer Paralympics and won gold at the 2016 Paralympic Games. Clearly up for any challenge, the sprinter is now competing in ITVs Dancing On Ice.

But why exactly is the star registered as blind? The sporting star has a deteriorating eye condition known as Stargardts Macular Dystrophy which gives her only slight peripheral vision in her left eye.

Libby has described her eyesight as being like looking at a pixelated computer screen or a scrunched-up firework, when speaking to The Daily mail.

She added: I have some peripheral sight - barely any - and with what little sight I do have I was able to use to use to follow the lines on the track.

Libby wasnt born blind, and started losing her eyesight at the age of 9.

But theres currently no treatment for Stargardt, and eventually, the mother-of-one will lose her entire sight.

She continued: Im at the age where my sight should be stabilising but its still deteriorating.

Things will never go black, but I dont know yet exactly what I will be able to see.

Speaking to The Radio Times about her learning process on the ice rink, Live explained: Its been a learning process.

DON'T MISS

On the track I run with a guide runner and were attached all the time, but basically its like learning a different vocabulary to communicate.

Myself and my partner Mark Hanretty use touch and verbal communication.

Im not as bad as I thought I was going to be, but its not as easy as it looks.

Its a lot harder than I thought itd be, its very technical."

Moorfields Eye Hospital, part of the NHS Foundation Trust, says Stargardt disease is a rare inherited condition affecting one in 8,000 to 10,000 people.

It explains: In Stargardts the light-sensitive layer of cells in the macular region of the eye degenerate.

The macular is the area at the back of the eye which is responsible for the fine detailed vision necessary for activities such as watching TV and reading.

Symptoms of the condition include:

Moorfields Eye Hospital says UV blocking sunglasses can offer some protection for remaining vision, but the condition is currently untreatable.

It adds: A number of novel interventions are currently under investigation, including stem cell therapies. Stem cells are a special type of cell which, when put under the right conditions, can develop into many other types of cell including those found in the macular. It is hoped that new cells derived from stem cells can be grown in a laboratory to be transplanted into the eye to replace areas of dead or non-functioning cells. Stem cells can be sourced from a number of places including blood, bone marrow, umbilical cord and fertilized egg cells.

Researchers are involved in Europes first ongoing stem cell trial for Stargardts. More research will need to be undertaken in the future to determine to what extent stem cell therapy might help improve vision for people with Stargardts.

Follow this link:
Libby Clegg health: Dancing On Ice star is registered blind - what is her condition? - Express

Bone Marrow Stem Cells Comments Off on Libby Clegg health: Dancing On Ice star is registered blind – what is her condition? – Express | January 19th, 2020

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology and Pharmaceuticals, Inc. (President and CEO: Jiwu Wang, Ph.D., Allele), a San Diego-based private company, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas), through its Massachusetts-based subsidiary Astellas Institute for Regenerative Medicine (AIRM), entered into a licensing agreement to expand Astellas access to Alleles induced pluripotent stem cell (iPSC) technologies for various cell therapy programs.

Astellas, one of the largest pharmaceutical companies in Japan and already a leader in the development of cell-based therapeutics, has further dedicated to development of the field through its commitment to state-of-the-art iPS cell generation, modification, and manufacturing. iPSC lines can differentiate into all somatic tissue types, enabling a wide variety of therapeutic applications. The field of iPSC-derived cells has seen dramatic growth in clinical trials recently--the majority of the ~12 clinical trials around the world were initiated within the last 18 months and many more are upcoming.

Allele has been developing its core strength in reprogramming somatic cells into iPSCs with granted patents and the first commercial cGMP system it developed over the past 10 years. Allele also engages in more than a dozen different human tissue derivation activities through its own R&D efforts for internal programs and partnerships. To realize the unparalleled potential of iPSC, Alleles researchers and cGMP team are committed to setting up and validating cell assays for product quality control, genome analysis pipelines, closed-system automation for reprogramming, and machine learning in iPSC-related fields.

Under the terms of the new license agreement, Astellas will pay Allele upfront and milestones, product-based royalties, and potentially manufacture fees.

About AlleleAllele Biotechnology and Pharmaceuticals was founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of GMP-grade human iPSC lines. The facility also supports the production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes.

More here:
Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire

IPS Cell Therapy Comments Off on Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines – Business Wire | January 19th, 2020

advertisement

Ryan Straschnitzki, a 20-year-old hockey player who was involved in the Humboldt Broncos bus crash is home after undergoing surgery in Thailand. Straschnitzki was paralyzed when the team bus hit a western semitrailer truck on April 6, 2018. 16 people on the bus were killed due to the horrific accident.

On Sunday evening, Straschnitzki left for Calgary Airport from Thailand. He told Global News, It feels good. I mean I felt the cold and cold wind hit my legs, so Im feeling good. Its good to be back.

We do it again. 35 days away. Big thanks for our looks at Thailand and Air Canada. Cant wait for Family Christmas Decoration. Quarreling. Haha. Ryan with his therapy cat, Bronze (Name after Dana) and Dexter. The hugs were big and long. pic.twitter.com/Ujshile6nd Strazsr (@strazsr) December 9, 2019

advertisement

Straschnitzki had been paralyzed from the chest down in the accident and had to have an epidural stimulant in his spine, along with the injected stem cells.

Straschnitzki is quoted as saying, It was extraordinary. I mean the last time I walked by my dad was before the accident and before I left. So doing it again and just looking into his eyes is motivating for me. .

His father, Tom, said: When I saw him actually moving his foot, it just made me imagine his last steps crossing that bus that lucky day. And I was just thinking that he might come back bus one day.

The surgery Straschnitzki requested has not yet been approved by Health Canada, or covered by public insurance, so it could cost close to $ 100,000. Because of this, Straschnitzki and his family had to make the trip to Thailand, unhappy with the Canadian healthcare system.

Our health care system is lacking in this area for spinal cord injuries and I think its great that Thailand and some other countries are starting this.

Licensed Spinal Stimulants are provided by Health Canada but are for pain relief only and not for motor skill recovery.

Just to get that feeling of being able to move something, that I wasnt able to move before, and know that core is a big part of my disability, so anything below my chest is essential. And after programming it really helped, Straschnitzki said.

He is planning to take some time off to rest before turning to ice and physiotherapy. Straschnitzki is also optimistic about making the Canadian Olympic hockey team sled in the future.

advertisement

Originally posted here:
The Canadian study finds that pregnant women should avoid marijuana - themediatimes

Spinal Cord Stem Cells Comments Off on The Canadian study finds that pregnant women should avoid marijuana – themediatimes | January 19th, 2020

No more feeling self-conscious about your scarring.

But there are other ingredients that aren't as harsh on the skin.

Salicylic acid is a fabulous way to combat acne in all skin types and can be found in a wash or in a lotion. If you tend to get small acne bumps known as comedonal acne, try OTC Differin lotion which is a retinoid. In general, those are strong enough to cause the skin to purge out those small bumps (which means it will be a little worse before getting better), and then prevent them from recurring, adds Dr. Mariwalla.

Contrary to what some people may think, having acne still means you need to moisturize. However, there are some precautions to consider. According to Dr. Mariwalla,Be sure not to use a heavy cream. Try a moisturizing gel or even a serum. A hyaluronic acid serum is ideal for acne=prone skin because it wont typically make you break out.

RELATED:20 Best Home Remedies For Acne Scars

Anti BacAcne Clearing Lotion is clinically proven to target pores to help clear existing acne, minimize excess oil production, and eliminate blackheads. Using an ultra-fine delivery system, benzoyl peroxide is delivered via a microscopic particle to affected areas, without over-drying.

(Sephora, $42)

Vichy Normaderm Beautifying Anti-Acne Treatment is an acne treatment moisturizer for adults with acne-prone skin. Thisnew formula with Air Licium and Phe resorcinoltechnology acts on the appearance of pores and shine. With salicylic acid to treat, blemishes disappear, leaving your skin looking radiant and beautiful.

(Check prices and reviews on Amazon)

Created by Beverly Hills plastic surgeons Dr. John Layke and Dr. Payman Danielpour, Beverly Hills MDAdvanced Scar Therapy contains advanced botanical ingredients that soothe and nourish damaged skinto dramatically diminish the appearance of stubborn scars. It contains an infusion of oxygen and antioxidants, for healthy-looking complexion and fewer visible imperfections.

(Beverly Hills MD, $80)

The Elina Organics Omega Serumcontains wild cod collagen, an antioxidant powerhouse that acts as a filler for scars. The serum promotes collagen regeneration and helps to firm, calm, and rejuvenate. Layer it with your nightly moisturizerfollowing exfoliation, and it helps your skin maintain its elasticity, increases hyaluronic acid production, and enhances skin hydration.

(ElinaOrganics, $52)

A powerful plant-based stem cell formulation decreases the appearance of fine lines, and softens and rejuvenates the skin. Stem cells help to support the longevity of aging skin by encouraging the regeneration of new skin cells, which stimulates the production of collagen in the skin.

(Knockout Beauty, $160)

Mela-Even Cream contains the lipid forms of the antioxidant vitamin C and E, which help to reclaim the appearance of healthy-looking, luminous skin. Not only does it help reduce scars, but it also helps to improve the appearance of uneven skin tone and fine lines, and assists in maintaining a healthy skin appearancewhile supporting its natural sun defence against the harmful effects of UV rays.

(Environ Skincare, $86)

This is a powerful skin lightening treatment gel featuring hydroquinone that rapidly reduces post-acne skin discoloration and helps combat breakouts. Willow bark and tea tree leaf extract help treat blemishes and reduce irritation as AHAs exfoliate to restore clarity and tone. This works best with normal, oily and combination skin types.

(Check prices and reviews on Amazon)

This treatment fights the main causes of acne by regulating skin cell turnover and reducing inflammation deep in the skin to clear and prevent pimples, blackheads and clogged pores. Differin contains the first OTC Rx-strength acne-fighting retinoid. Its gentler on your skin, while still effective, giving you the clearskin you want.

(Check prices and reviews on Amazon)

Neutrogena Rapid Tone Repair Dark Spot Corrector instantly brightens skin, with a high-potency fast absorbing formula that delivers the highest concentration of Vitamin C. With highly concentrated Accelerated Retinol SA, this advanced corrector works to renew the look of skin, brightening tone and helping fade stubborn dark spots and discoloration.

(Check prices and reviews on Amazon)

RELATED:How To Get Clear Skin Fast: 15 Tips For A Smooth, Acne-Free Complexion

Formulated with state-of-the-art UV filters, this high protection moisturizing sunscreen helps prevent UV induced collagen breakdown and UV-induced dark spots. It protectsskin from UVA and UVB rays, is easily absorbed into the skin, and comes in a lightweight formula.

(Check prices and reviews on Amazon)

Nia 24 Rapid D Tone Correcting Serum visibly diminishes the appearance of dark spots and discoloration to significantly improve brightness, clarity and tone. Vitamin C normalizes pigment production while increasing collagen and providing antioxidant protection. Willowbark extract exfoliates dull, dead skin cells while betaine smoothes the skin.

(Check prices and reviews on Amazon)

These powerful, easy-to-use pre-soaked pads are formulated with glycolic, lactic, citric, hyaluronic and salicylic acids, plus Pro-Vitamin B5 and Niacinamide that reduce pore size, fine lines, and wrinkles, and improve skin tone, texture and luminosity. Purslane Extract acts as a strong soother, itch reliever and antioxidant, and also promotes collagen production and cell turnover.

(Knockout Beauty, $79)

This pro-level retinol night treatment is formulated with 4.5 percent retinol in the patent-pending SB-100 delivery system, arguably one of the highest concentration in any over-the-counter retinol product. Retinol is the gold standard in treating acne scars by stimulating cell regeneration for brighter, more even skin. Clinical results show that 90 percent of subjects noticed an improvement in skin texture.

(Sephora, $105)

A medicated formula that exfoliates and reduces excess oil that can lead to breakouts. It unclogs pores and controls excess shine. Ingredients salicylic acid and acetyl glucosamine help clear dead skin cells that can contribute to clogged pores.Lamincaria Sacharina extract helps reduce shine and addresses future breakouts.

(Sephora, $17)

A unique and highly effective oil-free, non-comedogenic, lightweight moisturizer for combination to oily skin. Using clay that is mined in Umbria, Italy, it helps regulate sebum production, absorb impurities from blocked pores, calm flare-ups, and neutralize excess acidity on the skin which purifies and brightens the skin. This lightweight lotion gently hydrates, tones, and balances the complexion.

(Sephora, $38)

This is a redness-reducing lotion to help correct and prevent future blemishes. Ithelps to correct and prevent future blemishes, while reducing the appearance of dullness and rough texture. Formulated with acne-clearing salicylic acid and pine bark extract, this lotion calms and soothes redness and evens skin tone for a clearer complexion.

(Sephora, $48)

A gentle, oil-free exfoliating lotion for dry or combination skin. Developed by Clinique's dermatologists, the smoothing formula whisks away flakes and refines pores to reveal a clearer complexion. The cool, refreshing formula removes dead cells from the surface of the skin helping moisturizer and makeup to apply evenly.

(Sephora, $17)

This lightweight, oil-free moisturizer helps reduce shine and refine the appearance of pores for smoother skin texture without causing blemishes. Retinol supports natural cell turnover to help keep pores clear while hyaluronic acid and honey extract hydrate. Allantoin and arnica soothe, smooth, and condition skin.

(Sephora, $42)

This moisturizing treatment helps surround skin in an age-defending protective bubble. Silver tip white tea and revitalizing trehalose serve up an extra helping of hydration. It leaves skin soft and prepared for treatments to follow.

(Sephora, $27)

Fast-acting benzoyl peroxide attacks acne-causing bacteria to treat blackheads, blemishes and clogged pores at the source, and helps to control excess oil that can become trapped in pores and cause new breakouts. Botanical brighteners battle redness from existing and past blemishes, helping to fade the appearance of acne marks and reducing irritation from active breakouts. Antioxidants defend against the effects of free radical damage.

(Check prices and reviews on Amazon)

RELATED:21 Best Creams That Help Clear Up Scars

AlyWalanskyisa NY-basedlifestyles writer who focuses on health, wellness, and relationships. Her work appears in dozens of digital and print publications regularly.Visit her on Twitteroremail her.

YourTango may earn an affiliate commission if you buy something through links featured in this article.

Read the original post:
20 Best Lotions That Help Clear Up Acne Scars (And Moisturize Skin) - YourTango

Skin Stem Cells Comments Off on 20 Best Lotions That Help Clear Up Acne Scars (And Moisturize Skin) – YourTango | January 18th, 2020

A thorough study of the competitive landscape of the global Automotive Performance Tuning and Engine Remapping Services Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This research report will give a clear idea to readers about the overall market scenario to further decide on this market projects.

The report analysis the leading players of the global Automotive Performance Tuning and Engine Remapping Services market by inspecting their market share, recent developments, new product launches, partnerships, mergers, or acquisitions, and their target markets. This report also includes an exhaustive analysis of their product profiles to explore the products and applications their operations are concentrated on in the global Automotive Performance Tuning and Engine Remapping Services market. Additionally, the report gives two distinct market forecasts, one from the perspective of the producer and another from that of the consumer. It also offers valuable recommendations for new as well as established players of the global Automotive Performance Tuning and Engine Remapping Services market. It also provides beneficial insights for both new as well as established players of the global Automotive Performance Tuning and Engine Remapping Services market.

Request Sample Report @https://www.mrrse.com/sample/19752?source=atm

This report provides detailed historical analysis of global market for Automotive Performance Tuning and Engine Remapping Services from 2014-2019, and provides extensive market forecasts from 2019-2025 by region country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Automotive Performance Tuning and Engine Remapping Services market

some of the major players in the automotive performance tuning and engine remapping services market, such as Quantum Tuning, RS Tuning, Turbo Dynamics, EcuTek Technologies Ltd., Roo Systems, ABT Sportsline GmbH, and Tuning Works Inc.

Automotive Performance Tuning and Engine Remapping Services Market: Segmentation

By Vehicle Type

By Fuel Type

By Tuning Stage

By Tuning Method

By Application

By Region

Stage 1

Stage 2

Stage 3

Racing

Fuel Economizing

Performance Tuning

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa

Research Methodology

The initial stage of the research study includes the formulation of assumptions, which are necessary for primary and secondary research. Further stages of research involved the triangulation of the data collected from these two approaches. To analyse the global automotive performance tuning and engine remapping services market trends and opportunities for tuning service providers, the market has been segmented on the basis of vehicle type, fuel type, tuning stage, tuning method, application, and region.

For the analysis of service instances, we have considered FY 2018 as the base year. Basic data was collected from manufacturers annual reports, newsletters, public reports published by government, valve manufacturing organisations, private agencies, World Banks sources, etc.

For final analysis of the market data, we considered demand-side as well as supply-side drivers and trends in various regional markets. We have forecasted the market data on the basis of key developments, regional trends, and production-consumption scenario of the automotive performance tuning and engine remapping services market. For forecasting the market data, we have considered historic data for the period of 2014-2018.

The global Automotive Performance Tuning and Engine Remapping Services market research is carried out at the different stages of the business lifecycle from the production of a product, cost, launch, application, consumption volume and sale. The research offers valuable insights into the marketplace from the beginning including some sound business plans chalked out by prominent market leaders to establish a strong foothold and expand their products into one thats better than others.

We provide detailed product mapping and investigation of various market scenarios. Our expert analysts provide a thorough analysis and breakdown of the market presence of key market leaders. We strive to stay updated with the recent developments and follow the latest company news related to the industry players operating in the global Automotive Performance Tuning and Engine Remapping Services market. This helps us to comprehensively analysis the individual standing of the companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study to help you gain the upper hand in the competition.

Buy This Report @ https://www.mrrse.com/checkout/19752?source=atm

Reasons why you should buy this report

Understand the current and future of the Automotive Performance Tuning and Engine Remapping Services Market in both developed and emerging markets.

The report assists in realigning the business strategies by highlighting the Automotive Performance Tuning and Engine Remapping Services business priorities.

The report throws light on the segment expected to dominate the Automotive Performance Tuning and Engine Remapping Services industry and market.

Forecasts the regions expected to witness the fastest growth.

The latest developments in the Automotive Performance Tuning and Engine Remapping Services industry and details of the industry leaders along with their market share and strategies.

Saves time on the entry level analysis because the report contains very important info regarding growth, size, leading players and segments of the business.

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19752?source=atm

Table of Contents

Report Overview: It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Automotive Performance Tuning and Engine Remapping Services market segments by application, study objectives, and years considered.

Global Growth Trends: There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Automotive Performance Tuning and Engine Remapping Services Market Share by Manufacturer: Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type: It includes analysis of price, production value market share, and production market share by type.

Market Size by Application: This section includes Automotive Performance Tuning and Engine Remapping Services market consumption analysis by application.

Profiles of Manufacturers: Here, leading players of the global Automotive Performance Tuning and Engine Remapping Services market are studied based on sales area, key products, gross margin, revenue, price, and production.

Automotive Performance Tuning and Engine Remapping Services Market Value Chain and Sales Channel Analysis: It includes customer, distributor, Automotive Performance Tuning and Engine Remapping Services market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Continue reading here:
Stem Cell Therapy Market by Key Driver, Challenges and Opportunities in 2017 to 2025 - Fusion Science Academy

Spinal Cord Stem Cells Comments Off on Stem Cell Therapy Market by Key Driver, Challenges and Opportunities in 2017 to 2025 – Fusion Science Academy | January 18th, 2020

Thats something 13-year-old Floyd Korzan learned the hard way when his father, Matt, was diagnosed with acute myeloid leukemia, a highly-deadly form of blood cancer, after he fell ill on a family hiking trip in the Black Hills in 2012.

Matts fight against the disease has since taken the Mitchell family on a journey of frightening lows and celebratory highs and led Floyd to start Relentless Pledge, a non-profit organization that encourages patients to be as relentless as his father as they fight to achieve the goal of overcoming cancer.

We basically have two goals. The first one is to inspire others to overcome obstacles and dream their dreams. And the second part of the goal is to give a Relentless wristband to every cancer patient in Mitchell, our hometown, and eventually, if we get big enough, South Dakota and the United States, Floyd said in an interview with the Daily Republic.

Its a goal borne out of Floyds experience when he sat with his father at the Mayo Clinic in Rochester, Minnesota as he underwent treatments for the disease. Matt beat the leukemia once, but it later returned, a bad sign when associated with this particular kind of cancer. It went into remission again but returned again in 2017, and doctors were not hopeful.

With few options remaining, Matt agreed to a stem cell donation treatment that would use cells provided by his sister, Margaret, who happened to be a 100 percent match, injected into his system following an intense round of chemotherapy. The treatment was difficult, but after 8 million donor cells were circulated through his system, the doctors began to see good results.

Little by little, I came back, Matt said. After 30 days, they did a bone marrow biopsy that showed no evidence of leukemia whatsoever. They did another one at the end of the year, still no evidence of leukemia. They did one at the two-year mark, still no evidence of leukemia.

Visitors to relentlesspledge.org can nominate individuals to receive Relentless wristbands, which remind people to stay the course when attempting to achieve their goals. (Erik Kaufman / Republic)

Floyd recounted the scary days of his dads fight in an essay posted on his website relentlesspledge.org. He asked his father at the time how he could be as strong as he was even as he suffered from the disease and the side effects of his treatment. Matts response was that there may be times in life when the only person left who believes in you is you, and in those times, you must be relentless in order to make it through.

Floyd had found his own inspiration in his fathers fight, and he wanted to spread that inspiration to others who were suffering. Normally a private person, Matt agreed to share his story with the public and helped his son form Relentless Pledge, which encourages people to live life to the limit, to dare, to dream, and be relentless in overcoming challenges.

Visitors to the website can take the pledge, as well as nominate individuals to receive one of the symbols of the organization: a wristband bearing the word Relentless. Visitors can also order wristbands for themselves, family members, friends as well as cancer patients.

The goal is to spread the message of hope to every cancer patient in America, Floyd said. He has shipped orders of wristbands to 26 states around the country and three continents already, and the pair plan to pass out the wristbands to people in the leukemia ward at the Mayo Clinic, where Matt returns periodically for continued treatments. More wristbands will be given out at the Avera Cancer Center in Mitchell.

In total, they estimate theyve given out about 400 of them so far. And the campaign is officially less than two weeks old.

It seemed to strike a chord with people, Matt said.

As the young program grows, Floyd said the organization could expand to include more than just cancer patients in its message. There are others who are trying to accomplish goals, as well, such as public servants or community-minded individuals.

Its not all about cancer. Now were looking at giving them out to local heroes," Floyd said. "So far, weve given them to local firefighters and the librarians at the Mitchell Public Library, and were thinking about the police department."

Floyd hopes Relentless Pledge continues to grow. He is eyeing expanding the Relentless line to include t-shirts that would promote the Relentless Pledge, but for now he is concentrating on fulfilling orders for the wristbands and getting them in the hands of people who need inspiration.

I have big dreams in the future where this organization could expand to have a full line of accessories, Floyd said. Relentless gear.

Matt said he is recovering a little more each day, and hes grateful. Hes been able to throw the ball around in the yard with Floyd again, and he is working to become stronger as he continues his recovery. He said hes grateful for the love and support of Floyd as well as his wife Bam and other children Alexis, Cassidy, Hailey and Jackson. Hes thankful for doctors like Kebede Begna and Lucio Margallo, both of whom Matt described as relentless in helping him fight for his health.

And hes happy to help Floyd spread the message of hope through Relentless Pledge, he said.

I think its great. I think its a noble project, and I think its good for Floyd. Of all the ways a teenager can spend their time, this is pretty solid, Matt said.

Floyd said he plans to continue his work with the organization well into the future. He has a little over four years left before he leaves for college, and with that time he plans to do everything he can to remind those who are struggling to remain relentless.

One Relentless wristband at a time.

The next step is spreading the word, Floyd said.

The rest is here:
Learning to be relentless - The Daily Republic

Bone Marrow Stem Cells Comments Off on Learning to be relentless – The Daily Republic | January 18th, 2020

US Stem Cell (OTCMKTS:USRM) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Insider and Institutional Ownership

39.7% of National Research shares are held by institutional investors. 16.7% of US Stem Cell shares are held by company insiders. Comparatively, 4.5% of National Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

This table compares US Stem Cell and National Researchs net margins, return on equity and return on assets.

Valuation & Earnings

This table compares US Stem Cell and National Researchs top-line revenue, earnings per share (EPS) and valuation.

National Research has higher revenue and earnings than US Stem Cell.

Risk and Volatility

US Stem Cell has a beta of 4.87, suggesting that its share price is 387% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for US Stem Cell and National Research, as provided by MarketBeat.

Summary

National Research beats US Stem Cell on 7 of the 9 factors compared between the two stocks.

US Stem Cell Company Profile

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Companys portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Companys clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
US Stem Cell (OTCMKTS:USRM) and National Research (OTCMKTS:NRC) Head to Head Review - Slater Sentinel

Cardiac Stem Cells Comments Off on US Stem Cell (OTCMKTS:USRM) and National Research (OTCMKTS:NRC) Head to Head Review – Slater Sentinel | January 17th, 2020

An international collaboration called BioRescue has taken a step forward in bringing back the Northern White Rhino with the creation of three embryos, which it hopes to bring to term in a surrogate in the coming months.

The BioRescue team, including researchers based at the Leibniz Institute for Zoo and Wildlife Research, Germany, extracted egg cells from the ovaries of the last two remaining northern white rhino females. They then artificially fertilized the eggs using sperm taken from now-deceased male rhinos and stored the embryos in liquid nitrogen. The team managed to create two embryos in September 2019 and has recently created a third.

Before the BioRescue team came, no one had ever created an embryo from a northern white rhino except for the rhino itself, Steven Seet, Head Public Relations & International Affairs at the Leibniz Institute for Zoo and Wildlife Research, told me. This species is functionally extinct. Nevertheless, we have achieved the production of a third embryo now. This is incredible.

As the last two females are unable to become pregnant, the plan now is to implant the embryos into surrogate female southern white rhinos, a distinct subspecies, in the coming months. Every additional embryo increases the probability of getting a pregnancy The more, the better! Seet said.

There are many technical challenges remaining before the team can save the Northern White Rhino from extinction. First of all, it will need a lot more than three embryos to rebuild a healthy population. To meet this challenge, the team is developing technology to transform stem cells from northern white rhino skin tissue into egg and sperm cells. Our Japanese cooperation partner succeeded in doing so in a mouse model, Seet said. We are adapting this to the rhinos.

A second challenge may lie in implanting a northern white rhino embryo into a surrogate southern white rhino mother, which might have compatibility issues.

It might be that there are epigenetic components involved as the biological system of the southern rhinos might differ from the northern, Seet told me. A possible assessment of this could be conducted when we have the first calves on the ground. This is further research then.

Also involved in the BioRescue project was the German big pharma Merck KGaA, which donated a specialized incubator where the egg cells could be fertilized with monitoring by HD cameras.

Merck has donated access to its innovative fertility technologies to Project BioRescue to give this challenge the best possible chance of success and protect the Northern White Rhino from extinction, Jan Kirsten, Mercks Head of Global Business Franchise for Fertility, told me. While there is a long way to go on this journey, we hope these steps will pave the way for this technique to potentially be used in other species.

According to Kirsten and Seet, the biotechnology industry will likely play a strong role in the conservation of endangered species in the coming years. However, argued Seet, reproductive medicine and stem cell technology should remain a last resort to save a species.

It would be better to react much earlier to avoid using the BioRescue technology, he said. Humans must learn from this best practice project and evaluate biodiversity and conserve it.

Images from Shutterstock

View post:
International Collaboration on Brink of Resurrecting Northern White... - Labiotech.eu

Skin Stem Cells Comments Off on International Collaboration on Brink of Resurrecting Northern White… – Labiotech.eu | January 17th, 2020